Fractyl Health (NASDAQ:GUTS) Stock Price Down 6.2%

Fractyl Health, Inc. (NASDAQ:GUTSGet Free Report) shares fell 6.2% during trading on Wednesday . The company traded as low as $7.10 and last traded at $7.20. 154,712 shares were traded during trading, a decline of 63% from the average session volume of 422,425 shares. The stock had previously closed at $7.68.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on GUTS. Bank of America began coverage on Fractyl Health in a research report on Tuesday, February 27th. They issued a “buy” rating and a $26.00 price objective on the stock. Evercore ISI began coverage on Fractyl Health in a research report on Wednesday, February 28th. They issued an “outperform” rating on the stock. Finally, Morgan Stanley began coverage on Fractyl Health in a research report on Tuesday, February 27th. They issued an “overweight” rating and a $18.00 price objective on the stock.

Read Our Latest Report on GUTS

Fractyl Health Stock Performance

Insider Activity at Fractyl Health

In other Fractyl Health news, Director Ajay Royan bought 333,333 shares of the company’s stock in a transaction that occurred on Tuesday, February 6th. The stock was purchased at an average cost of $15.00 per share, for a total transaction of $4,999,995.00. Following the completion of the purchase, the director now owns 1,251,900 shares of the company’s stock, valued at approximately $18,778,500. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

About Fractyl Health

(Get Free Report)

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.

Featured Stories

Receive News & Ratings for Fractyl Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fractyl Health and related companies with MarketBeat.com's FREE daily email newsletter.